<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg"/></p>
<p>安進正在收購總部位於英國的生物技術公司 Dark Blue Therapeutics，收購金額高達 8.4 億美元。圖片來源：Piotr Swat via ShutterStock.com。</p>
<p>安進已同意以高達 8.4 億美元的價格收購總部位於英國的生物技術公司 Dark Blue Therapeutics，這標誌着 2026 年的首筆製藥收購。</p>
<p>通過此次交易，安進將獲得 Dark Blue 的腫瘤學資產管線，包括 DBT 3757，這是一種針對髓系/淋巴系白血病易位 1 和 3（MLLT1/3）的研究性蛋白降解劑。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Agenus Inc 的 Botensilimab</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Amgen Inc 的 Tarlatamab</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現有效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>目前正在進行研究性新藥（IND）啓用研究，DBT 3757 正在開發用於急性髓系白血病（AML）的治療，前期臨牀工作已經突顯了其抗癌潛力。</p>
<p>根據 Dark Blue 的説法，該療法與市場上已上市治療的差異機制，以及其增強 AML 緩解持久性的潛力，為該藥物的進一步開發提供了合理依據，可能作為單藥治療或與其他 AML 治療選項聯合使用。</p>
<p>安進研發執行副總裁 Jay Bradner 指出，此次收購將有助於公司 “早期投資新興藥物” 的戰略，這些藥物利用新型治療靶點。</p>
<p>花旗分析師對此表示贊同，指出：“Dark Blue 的研究機構與安進的整合預計將進一步推動早期腫瘤學管線的實力。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>在此次合併後，預計 Dark Blue Therapeutics 將整合到安進現有的研究部門中。</p>
<h2>安進加大交易策略</h2>
<p>安進收購 Dark Blue Therapeutics 標誌着這家總部位於加利福尼亞的製藥公司自 2023 年以 278 億美元收購生物製藥公司 Horizon Therapeutics 以來的首次併購活動。這結束了安進的交易乾旱期，該公司在 2024 年分別簽署了一項許可和開發協議，而在 2025 年沒有獲得此類交易的批准。</p>
<p>安進在 2026 年似乎處於交易的前沿。在宣佈收購 Dark Blue 的一天後，安進透露已與 DISCO Pharmaceuticals 簽署了一項價值高達 6.18 億美元的腫瘤學許可協議。</p>
<p>除了在腫瘤學方面的動作，安進還在關注肥胖領域，這是 禮來 和 諾和諾德 通過各自的胰高血糖素樣肽-1 受體激動劑（GLP-1RAs）實現高藥品銷售的領域。</p>
<p>安進有自己的研究性 GLP-1 激動劑和葡萄糖依賴性胰島素促分泌多肽受體（GIP）拮抗劑，名為 maridebart carfraglutide，也稱為 MariTide。</p>
<p>儘管 GlobalData 分析師和關鍵意見領袖之前對該療法抱有 很高的期望，稱其在肥胖領域可能是一個 “遊戲規則改變者”，但關於該藥物可能 降低骨密度 的擔憂已被提出。然而，安進對此進行了反駁，表示公司 “沒有看到 MariTide 的使用與骨礦密度變化之間的關聯”。</p>
<p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>
<p>儘管發展道路坎坷，安進正在推進 MariTide 的後期開發計劃。</p>
<p>根據花旗分析師的説法，安進的肥胖管線將 “在敍述中保持關鍵地位”。</p>

安進

<p>安進正在以高達 8.4 億美元收購總部位於英國的生物技術公司 Dark Blue Therapeutics，這標誌着 2026 年的首次製藥行業收購。這項收購將增強安進的腫瘤學產品線，特別是針對急性髓性白血病的研究藥物 DBT 3757。分析師認為，整合 Dark Blue 的研究可能會加強安進在早期腫瘤學方面的努力。在達成此交易後，安進還與 DISCO Pharmaceuticals 簽署了一項價值 6.18 億美元的腫瘤學許可協議，顯示出在一段時間的停滯後，安進重新關注交易活動</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2411585553-430x241.jpg"/></p>
<p>Amgen is acquiring UK-based biotech Dark Blue Therapeutics in a buyout worth up to $840m. Image credit: Piotr Swat via ShutterStock.com.</p>
<div class="lb-trans"><p>安進正在收購總部位於英國的生物技術公司 Dark Blue Therapeutics，收購金額高達 8.4 億美元。圖片來源：Piotr Swat via ShutterStock.com。</p>
</div><p>Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover of 2026.</p>
<div class="lb-trans"><p>安進已同意以高達 8.4 億美元的價格收購總部位於英國的生物技術公司 Dark Blue Therapeutics，這標誌着 2026 年的首筆製藥收購。</p>
</div><p>Through this transaction, Amgen will gain access to Dark Blue’s pipeline of oncology assets – including DBT 3757, an investigational myeloid/lymphoid leukaemia translocation 1 and 3 (MLLT1/3)-targeted protein degrader.</p>
<div class="lb-trans"><p>通過此次交易，安進將獲得 Dark Blue 的腫瘤學資產管線，包括 DBT 3757，這是一種針對髓系/淋巴系白血病易位 1 和 3（MLLT1/3）的研究性蛋白降解劑。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Agenus Inc's Botensilimab</h4>
<div class="lb-trans"><h4>NPVM: Agenus Inc 的 Botensilimab</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Amgen Inc's Tarlatamab</h4>
<div class="lb-trans"><h4>NPVM: Amgen Inc 的 Tarlatamab</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現有效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Currently in investigational new drug (IND)-enabling studies, DBT 3757 is being developed for the treatment of acute myeloid leukaemia (AML), with preclinical work having already highlighted its anticancer potential.</p>
<div class="lb-trans"><p>目前正在進行研究性新藥（IND）啓用研究，DBT 3757 正在開發用於急性髓系白血病（AML）的治療，前期臨牀工作已經突顯了其抗癌潛力。</p>
</div><p>According to Dark Blue, the therapy’s differential mechanism to marketed treatments, as well as its potential to boost the durability of AML remission, builds rationale for the drug’s further development, which may be used both as a monotherapy and in combination with other AML treatment options.</p>
<div class="lb-trans"><p>根據 Dark Blue 的説法，該療法與市場上已上市治療的差異機制，以及其增強 AML 緩解持久性的潛力，為該藥物的進一步開發提供了合理依據，可能作為單藥治療或與其他 AML 治療選項聯合使用。</p>
</div><p>Amgen’s executive VP of R&amp;D, Jay Bradner, noted that the acquisition would assist the company’s strategy of “investing early into rising medicines” that harness novel therapeutic targets.</p>
<div class="lb-trans"><p>安進研發執行副總裁 Jay Bradner 指出，此次收購將有助於公司 “早期投資新興藥物” 的戰略，這些藥物利用新型治療靶點。</p>
</div><p>Citi analysts echoed this sentiment, noting: “The anticipated integration of Dark Blue’s research organisation into Amgen could further drive early oncology pipeline strength.”</p>
<div class="lb-trans"><p>花旗分析師對此表示贊同，指出：“Dark Blue 的研究機構與安進的整合預計將進一步推動早期腫瘤學管線的實力。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>Following this merger, Dark Blue Therapeutics is anticipated to integrate into Amgen’s existing research division.</p>
<div class="lb-trans"><p>在此次合併後，預計 Dark Blue Therapeutics 將整合到安進現有的研究部門中。</p>
</div><h2>Amgen ramps up dealmaking strategy</h2>
<div class="lb-trans"><h2>安進加大交易策略</h2>
</div><p>Amgen’s acquisition of Dark Blue Therapeutics marks the first M&amp;A activity the California-based pharma has engaged in since its $27.8bn acquisition of biopharmaceutical company Horizon Therapeutics in 2023.  This puts an end to a deal drought for Amgen, which saw the company sign one licensing and development agreement, respectively, in 2024, with no deals of this nature getting the green light in 2025.</p>
<div class="lb-trans"><p>安進收購 Dark Blue Therapeutics 標誌着這家總部位於加利福尼亞的製藥公司自 2023 年以 278 億美元收購生物製藥公司 Horizon Therapeutics 以來的首次併購活動。這結束了安進的交易乾旱期，該公司在 2024 年分別簽署了一項許可和開發協議，而在 2025 年沒有獲得此類交易的批准。</p>
</div><p>Amgen appears to be on the dealmaking front foot in 2026. A day after announcing the Dark Blue takeover, Amgen revealed it had signed an oncology licensing deal with DISCO Pharmaceuticals worth up to $618m.</p>
<div class="lb-trans"><p>安進在 2026 年似乎處於交易的前沿。在宣佈收購 Dark Blue 的一天後，安進透露已與 DISCO Pharmaceuticals 簽署了一項價值高達 6.18 億美元的腫瘤學許可協議。</p>
</div><p>Alongside its movements in oncology, Amgen is eyeing entry into the obesity segment, an area where Eli Lilly and Novo Nordisk have recorded high drug sales through their respective glucagon-like peptide-1 receptor agonists (GLP-1RAs).</p>
<div class="lb-trans"><p>除了在腫瘤學方面的動作，安進還在關注肥胖領域，這是 禮來 和 諾和諾德 通過各自的胰高血糖素樣肽-1 受體激動劑（GLP-1RAs）實現高藥品銷售的領域。</p>
</div><p>Amgen has its own investigational GLP-1 agonist and glucose-dependent insulinotropic polypeptide receptor (GIP) antagonist called maridebart carfraglutide – otherwise known as MariTide.</p>
<div class="lb-trans"><p>安進有自己的研究性 GLP-1 激動劑和葡萄糖依賴性胰島素促分泌多肽受體（GIP）拮抗劑，名為 maridebart carfraglutide，也稱為 MariTide。</p>
</div><p>While GlobalData analysts and key opinion leaders previously had high hopes for the therapy, calling it a potential “game changer” within the obesity space, concerns around the drug’s potential to diminish bone density have been raised. However, Amgen has refuted these claims, stating that the company “does not see an association between the administration of MariTide and bone mineral density changes”.</p>
<div class="lb-trans"><p>儘管 GlobalData 分析師和關鍵意見領袖之前對該療法抱有 很高的期望，稱其在肥胖領域可能是一個 “遊戲規則改變者”，但關於該藥物可能 降低骨密度 的擔憂已被提出。然而，安進對此進行了反駁，表示公司 “沒有看到 MariTide 的使用與骨礦密度變化之間的關聯”。</p>
</div><p>GlobalData is the parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>
</div><p>Despite its rocky development path, Amgen is advancing MariTide’s late-stage development programme.</p>
<div class="lb-trans"><p>儘管發展道路坎坷，安進正在推進 MariTide 的後期開發計劃。</p>
</div><p>According to Citi analysts, Amgen’s obesity pipeline will “remain key to the narrative”.</p>
<div class="lb-trans"><p>根據花旗分析師的説法，安進的肥胖管線將 “在敍述中保持關鍵地位”。</p>
</div>

安進以 8.4 億美元收購 Dark Blue Therapeutics，達成腫瘤領域的交易